WO2004003145A3 - Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds - Google Patents
Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds Download PDFInfo
- Publication number
- WO2004003145A3 WO2004003145A3 PCT/US2003/019994 US0319994W WO2004003145A3 WO 2004003145 A3 WO2004003145 A3 WO 2004003145A3 US 0319994 W US0319994 W US 0319994W WO 2004003145 A3 WO2004003145 A3 WO 2004003145A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epithelial
- compositions
- methods
- adhesion molecules
- permeabilizing agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03742185A EP1539208A2 (en) | 2002-06-28 | 2003-06-24 | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
JP2004517800A JP2005537244A (en) | 2002-06-28 | 2003-06-24 | Compositions and methods for modulating physiological function of epithelial junction adhesion molecules for enhancing mucosal delivery of therapeutic compounds |
AU2003279750A AU2003279750A1 (en) | 2002-06-28 | 2003-06-24 | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
CA002487712A CA2487712A1 (en) | 2002-06-28 | 2003-06-24 | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39251202P | 2002-06-28 | 2002-06-28 | |
US60/392,512 | 2002-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004003145A2 WO2004003145A2 (en) | 2004-01-08 |
WO2004003145A3 true WO2004003145A3 (en) | 2004-06-10 |
Family
ID=30000886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/019994 WO2004003145A2 (en) | 2002-06-28 | 2003-06-24 | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040077540A1 (en) |
EP (1) | EP1539208A2 (en) |
JP (1) | JP2005537244A (en) |
AU (1) | AU2003279750A1 (en) |
CA (1) | CA2487712A1 (en) |
WO (1) | WO2004003145A2 (en) |
ZA (1) | ZA200410287B (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
AU2003248888A1 (en) * | 2002-07-09 | 2004-01-23 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
JP4903036B2 (en) * | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | Aprotinin and analogs as carriers that cross the blood brain barrier |
US20040258663A1 (en) * | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
WO2005016111A2 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
US20050129679A1 (en) * | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
RU2006143544A (en) * | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | COMPOSITIONS AND METHOD FOR LIGHTENED TRANSMISSION DELIVERY OF PARATHYROID HORMONE |
US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
EP1768647B1 (en) * | 2004-06-17 | 2012-08-08 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent |
US20060062758A1 (en) * | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
MX2007005790A (en) * | 2004-11-16 | 2007-09-11 | Limerick Neurosciences Inc | Methods and compositions for treating pain. |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
PL1859041T5 (en) * | 2005-02-18 | 2015-05-29 | Angiochem Inc | Aprotinin polypeptides for transporting a compound across the blood-brain barrier |
GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
AU2006257792A1 (en) * | 2005-06-13 | 2006-12-21 | Mdrna, Inc. | Transmucosal delivery of peptide derivatives |
EP2471555A3 (en) | 2005-07-15 | 2012-10-17 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
US20090220435A1 (en) | 2005-07-27 | 2009-09-03 | Nastech Pharmaceutical Company Inc. | Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents |
US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
US20070154449A1 (en) * | 2005-12-16 | 2007-07-05 | Nastech Pharmaceutical Company Inc. | Tight junction modulating peptides for enhanced mucosal delivery of therapeutic compounds |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
DK2148691T3 (en) | 2007-02-05 | 2015-08-17 | Apellis Pharmaceuticals Inc | Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system |
US8512693B2 (en) * | 2007-02-14 | 2013-08-20 | Northwestern University | Self-assembling membranes and related methods thereof |
US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
ES2539818T3 (en) * | 2007-08-02 | 2015-07-06 | Biondvax Pharmaceuticals Ltd. | Multimeric multi-epitopic flu vaccines |
WO2009027697A2 (en) * | 2007-08-31 | 2009-03-05 | Archimedes Development Limited | Non-aqueous pharmaceutical compositions |
EP2030610A1 (en) * | 2007-08-31 | 2009-03-04 | Archimedes Development Limited | Non-aqueous pharmaceutical compositions |
US9540649B2 (en) | 2007-10-12 | 2017-01-10 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Method for opening tight junctions |
WO2009049365A1 (en) * | 2007-10-15 | 2009-04-23 | Cooperative Research Centre For Asthma | A method of prophylaxis and agents for use therein |
RU2518240C2 (en) * | 2008-04-18 | 2014-06-10 | Ангиочем Инк. | Composition based on hydrophobic agents and method for preparing it (versions) |
EP2346896A4 (en) | 2008-10-15 | 2014-06-25 | Angiochem Inc | Etoposide and doxorubicin conjugates for drug delivery |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
CA2745524C (en) * | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
MX2011006685A (en) | 2008-12-17 | 2011-09-27 | Angiochem Inc | Membrane type-1 matrix metalloprotein inhibitors and uses thereof. |
US20120058956A1 (en) * | 2009-03-03 | 2012-03-08 | Metamorefix Ltd. | Peptides derived from ficolin as surfactants |
JP2012520686A (en) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MX2011009724A (en) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING. |
JP2012521762A (en) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of nerve growth factor β chain (NGFβ) gene expression using small interfering nucleic acids (siNA) |
EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111497A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
US8263581B2 (en) * | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
WO2011128884A1 (en) * | 2010-04-11 | 2011-10-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Extract and peptides derived from oryza sativa japonica group and uses thereof |
JP6043285B2 (en) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA) |
LT2606134T (en) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US9233997B2 (en) | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
CN103619879A (en) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | Anti-ngf compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
DK2646035T3 (en) | 2010-12-02 | 2016-05-30 | Univ Kansas | PRO-DRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDINE-2 (1H) -ON AND DERIVATIVES THEREOF |
WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
EP2561886A1 (en) * | 2011-08-23 | 2013-02-27 | Forschungsverbund Berlin e.V. | Peptide adjuvant for improved peripheral analgesia |
BR112014014868B1 (en) * | 2011-12-19 | 2022-12-27 | Genzyme Corporation | THYROID STIMULATING HORMONE COMPOSITIONS, METHODS OF PRODUCING THE SAME AND USE OF SUCH COMPOSITIONS |
US20150031610A1 (en) * | 2012-03-05 | 2015-01-29 | Synedgen, Inc. | Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
KR20150090917A (en) | 2012-12-06 | 2015-08-06 | 머크 샤프 앤드 돔 코포레이션 | Disulfide masked prodrug compositions and methods |
CN103146779B (en) * | 2013-04-02 | 2014-07-30 | 南京工业大学 | Method of synthesizing trehalose by virtue of whole cell catalysis |
US10426828B2 (en) | 2014-04-03 | 2019-10-01 | Biondvax Pharmaceuticals Ltd. | Compositions of multimeric-multiepitope influenza polypeptides and their production |
CN103923216B (en) * | 2014-04-22 | 2016-04-27 | 吉林大学 | Multifunction module fusion rotein and the application in raising protein drug oral administration biaavailability thereof |
EP3145533A2 (en) | 2014-05-23 | 2017-03-29 | Reponex Pharmaceuticals APS | Compositions for promoting the healing of wounds |
EP3848047A1 (en) | 2014-07-24 | 2021-07-14 | Reponex Pharmaceuticals APS | Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
DK3307326T3 (en) | 2015-06-15 | 2020-10-19 | Angiochem Inc | METHODS FOR THE TREATMENT OF LEPTOMENINGAL CARCINOMATOSIS |
EP3532031A4 (en) * | 2016-10-26 | 2020-06-03 | Revive Pharmaceuticals, LLC | Treating sexual dysfunction |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10738079B2 (en) * | 2017-04-14 | 2020-08-11 | Emory University | Compositions and methods for managing respiratory conditions |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019165346A1 (en) * | 2018-02-23 | 2019-08-29 | Innovate Biopharmaceuticals, Inc. | Compounds and methods for treating tight junction permeability |
JPWO2019221039A1 (en) * | 2018-05-14 | 2021-05-13 | 公立大学法人福島県立医科大学 | Cell culture aid |
JP2021529220A (en) | 2018-09-20 | 2021-10-28 | リーヴォ セラピューティクス, インコーポレイテッド | Stable intranasal preparation of carbetocin |
KR20210062648A (en) | 2018-09-20 | 2021-05-31 | 레보 테라퓨틱스 인코포레이티드 | Carbetocin drug product and method of manufacturing the same |
US10413556B1 (en) * | 2019-03-21 | 2019-09-17 | Moshe Shifrine | Production of insulin by testosterone olfaction |
EP3955936A1 (en) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110747A (en) * | 1997-12-31 | 2000-08-29 | Adherex Technologies Inc. | Compounds and methods for modulating tissue permeability |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5554388A (en) * | 1989-02-25 | 1996-09-10 | Danbiosyst Uk Limited | Systemic drug delivery compositions comprising a polycationi substance |
SE8904296D0 (en) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | TRANSDERMAL SYSTEM |
JPH0532696A (en) * | 1990-09-28 | 1993-02-09 | Takeda Chem Ind Ltd | Parathyroid hormone derivative |
JPH07503154A (en) * | 1992-01-21 | 1995-04-06 | エス・アール・アイ・インターナシヨナル | Improved preparation method for miniaturized polypeptide drugs |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
TW460296B (en) * | 1994-09-01 | 2001-10-21 | Janssen Pharmaceutica Nv | Topical ketoconazole emulsion compositions without sodium sulfite |
GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
EP0908181B8 (en) * | 1996-05-20 | 2009-04-15 | Otsuka Pharmaceutical Co., Ltd. | Remedy for rosacea |
GB9707934D0 (en) * | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
AU751182B2 (en) * | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
US20030017497A1 (en) * | 1998-02-04 | 2003-01-23 | Thomas Kieber-Emmons | Peptide mimotopes of carbohydrate antigens |
US6960566B1 (en) * | 1998-11-06 | 2005-11-01 | The Wister Institute of Anatomy and Biology | Compositions and methods for treatment of cancer |
US6391855B1 (en) * | 1999-06-02 | 2002-05-21 | Adherex Technologies, Inc. | Compounds and methods for modulating junctional adhesion molecule-mediated functions |
CA2382783A1 (en) * | 1999-08-24 | 2001-03-01 | Texas Biotechnology Corporation | A polynucleotide encoding a human junctional adhesion protein (jam-2) |
GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
US20040258663A1 (en) * | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
-
2003
- 2003-06-24 EP EP03742185A patent/EP1539208A2/en not_active Withdrawn
- 2003-06-24 JP JP2004517800A patent/JP2005537244A/en not_active Withdrawn
- 2003-06-24 AU AU2003279750A patent/AU2003279750A1/en not_active Abandoned
- 2003-06-24 WO PCT/US2003/019994 patent/WO2004003145A2/en active Application Filing
- 2003-06-24 CA CA002487712A patent/CA2487712A1/en not_active Abandoned
- 2003-06-24 US US10/601,953 patent/US20040077540A1/en not_active Abandoned
-
2004
- 2004-12-21 ZA ZA200410287A patent/ZA200410287B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110747A (en) * | 1997-12-31 | 2000-08-29 | Adherex Technologies Inc. | Compounds and methods for modulating tissue permeability |
US6248864B1 (en) * | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
Non-Patent Citations (1)
Title |
---|
AURRAND-LIONS ET AL.: "JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2733 - 2741, XP002972606 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003279750A1 (en) | 2004-01-19 |
CA2487712A1 (en) | 2004-01-08 |
EP1539208A2 (en) | 2005-06-15 |
JP2005537244A (en) | 2005-12-08 |
US20040077540A1 (en) | 2004-04-22 |
ZA200410287B (en) | 2005-11-18 |
WO2004003145A2 (en) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004003145A3 (en) | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds | |
WO2006044596A8 (en) | Multi-domain amphipathic helical peptides and methods of their use | |
EP2267027A3 (en) | Method of administering therapeutic polypeptides, and polypeptides therefor | |
WO2006088508A3 (en) | Cupredoxin derived transport agents and methods of use thereof | |
EP1900753A3 (en) | Method of administering therapeutic polypeptides, and polypeptides therefor | |
AU2003266159A1 (en) | System and method for delivering a composition to the nasal membrane | |
WO2007104062A3 (en) | Compositions and methods based on peptide binding profiling | |
WO2009133137A3 (en) | Pegylated recombinant human growth hormone compounds | |
MX2009013372A (en) | Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury. | |
EP2409988A3 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
EP1137658A4 (en) | METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | |
AU2003261165A1 (en) | Improved fuel delivery system | |
RS20070027A (en) | Anti-cd154 antibodies | |
WO2007012004A3 (en) | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof | |
BRPI0513477A (en) | Angiotensin-like protein 4 compositions and processes | |
AU2003222067A1 (en) | System for delivery of therapeutic substances | |
IL147138A0 (en) | Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation | |
WO2003070892A3 (en) | Inhibitors of rgs proteins | |
WO2009081368A3 (en) | Cosmetic use desmoglein i-type proteins | |
WO2008103378A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
AU2003301444A1 (en) | System for delivery of active substances | |
WO2007109648A3 (en) | Compositions and methods for modulating store-operated calcium entry | |
WO2004112820A3 (en) | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity | |
AU2003272517A1 (en) | Compositions to reduce congestion and methods for application thereof to the nasal membrane | |
EP1779860A3 (en) | The chromatin peptides blocking human HIF-1a gene and modulating the downstream related genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2487712 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01951/KOLNP/2004 Country of ref document: IN Ref document number: 1951/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/10287 Country of ref document: ZA Ref document number: 200410287 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004517800 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003279750 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537569 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003742185 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003742185 Country of ref document: EP |